Cerity Partners
PRLD icon

Cerity Partners’s Prelude Therapeutics PRLD Stock Holding History

Cerity Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Hold
32,875
– – ﹤0.01% 3085
2026
Q1 		$112K Sell
32,875
-78
-0.2% -$205 ﹤0.01% 3006
2025
Q4 		$95.6K Sell
32,953
-1,380
-4% -$2.33K ﹤0.01% 2754
2025
Q3 		$49.4K Sell
34,333
-2,060
-6% -$2.06K ﹤0.01% 2697
2025
Q2 		$29.5K Buy
36,393
+1,828
+5% +$1.58K ﹤0.01% 2590
2025
Q1 		$26.5K Buy
34,565
+1,688
+5% +$1.58K ﹤0.01% 2434
2024
Q4 		$68.1K Buy
32,877
+2
+0% +$3 ﹤0.01% 2369
2024
Q3 		$68.1K Buy
+32,875
New +$152K ﹤0.01% 2462
2024
Q2 		– Sell
-32,500
Closed -$154K – 2374
2024
Q1 		$154K Buy
+32,500
New +$126K ﹤0.01% 2155

Other funds holding PRLD

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sphera Funds Management
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ADAR1 Capital Management
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Cerity Partners's PRLD Position: Q2 2026 in Review

Cerity Partners held its Prelude Therapeutics (PRLD) position steady in Q2 2026 at 32,875 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #3085.

Cerity Partners first reported a position in PRLD in Q1 2024 and has held it in 9 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Cerity Partners held 32,875 shares of Prelude Therapeutics worth $175K as of Q2 2026.
  • Cerity Partners left its Prelude Therapeutics share count unchanged in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3085 holding.
  • Cerity Partners first reported a position in Prelude Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.